New study aims to cut relapse in tough blood cancers after transplant
NCT ID NCT07319793
First seen Jan 11, 2026 · Last updated Jun 09, 2026 · Updated 31 times
Summary
This study compares two methods of giving donor immune cells (donor lymphocyte infusion) after a stem cell transplant to prevent cancer from coming back in people with hard-to-treat acute myeloid leukemia or myelodysplastic syndromes. About 200 participants will be randomly assigned to receive donor cells either as a preventive measure or only when signs of remaining cancer appear. The goal is to see which approach lowers relapse rates and improves survival without causing severe side effects like graft-versus-host disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.